Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

Rhea-AI Summary

Revolution Medicines, Inc. (RVMD) will present multiple groundbreaking discoveries at the AACR Annual Meeting 2024, focusing on innovative therapies for RAS-addicted cancers. Key presentations include new RAS inhibitors, combination therapies, and potential biomarkers. The company aims to address drug resistance and enhance treatment outcomes for cancer patients.

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:	Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor
Presenter:	John Knox, Ph.D.
Abstract Number:	ND03
Session:	New Drugs on the Horizon: Part 1
Date/Time:	1:45 – 2:00 p.m. PT on April 7, 2024
Title:	RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor
Presenter:	Elena Koltun, Ph.D., Wei Lin, M.D.
Session:	KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology
Date/Time:	1:00 – 1:20 p.m. PT on April 9, 2024
Title:	Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC
Presenter:	Xing Wei, Ph.D.
Abstract Number:	6585
Session:	Novel Antitumor Agents 5
Date/Time:	2:35 – 2:50 p.m. PT on April 9, 2024

Revolution Medicines Poster Presentations:

Title:	Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models
Presenter:	Lillian Seu, Ph.D.
Abstract Number:	581/4
Session:	Immunotherapy
Date/Time:	1:30 – 5:00 p.m. PT on April 7, 2024
Title:	RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors
Presenter:	Zhe Chen, M.B.B.S., Ph.D.
Abstract Number:	3340/28
Session:	Novel Antitumor Agents 3
Date/Time:	1:30 – 5:00 p.m. PT on April 8, 2024
Title:	The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers
Presenter:	Priyanka Bapat, Ph.D.
Abstract Number:	4709/2
Session:	Other Cellular Mechanisms for Anticancer Drug Action
Date/Time:	9:00 a.m. – 12:30 p.m. PT on April 9, 2024

Collaborator Poster Presentations:

Title:	RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models
Lead RevMed Co-Author:	Harshit Shah, Ph.D.
Abstract Number:	1924/2
Session:	Drug Resistance 2: RAS GTPase
Date/Time:	9:00 a.m. – 12:30 p.m. PT on April 8, 2024
Title:	Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors
Lead RevMed Co-Author:	Jingjing Jiang, Ph.D.
Abstract Number:	1927/5
Session:	Drug Resistance 2: RAS GTPase
Date/Time:	9:00 a.m. – 12:30 p.m. PT on April 8, 2024

Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

FAQ

What is Revolution Medicines (RVMD) presenting at the AACR Annual Meeting 2024?

Revolution Medicines will present new RAS inhibitors, combination therapies, and potential biomarkers at the AACR Annual Meeting 2024.

When and where is the AACR Annual Meeting 2024 taking place?

The AACR Annual Meeting 2024 will be held in San Diego, California, from April 5-10, 2024.

Who are some of the presenters from Revolution Medicines (RVMD) at the AACR Annual Meeting 2024?

Presenters from Revolution Medicines include John Knox, Elena Koltun, Wei Lin, Xing Wei, Lillian Seu, Zhe Chen, and Priyanka Bapat.

What is the focus of Revolution Medicines (RVMD) presentations at the AACR Annual Meeting 2024?

Revolution Medicines' presentations will focus on developing targeted therapies for RAS-addicted cancers and addressing drug resistance in cancer treatment.

Where can more information about the AACR Annual Meeting 2024 be found?

Additional information about the AACR Annual Meeting 2024 is available on the AACR website.